Valbiotis, Successfully

Valbiotis (FR0013254851 – ALVAL, PEA / SME eligible), a Research and Development company committed to scientific innovation for preventing and combating metabolic and cardiovascular diseases, today announces the success of its fundraise for approximatively € 9.7 millions, including, on the one hand, a reserved offer intended to a category of investors via an accelerated bookbuilding for approximately €9.0 million, and, on the other hand, an offer to the public intended to individual shareholders via the PrimaryBid platform of approximately €0.7 million (the “Global Offer”).

09.11.2022 - 08:32:30

Valbiotis Successfully Completes a Fundraise of 9.7 Million Euros

and September 15, 2022) and at the latest until July 31, 2023. This commitment was made subject to the usual exceptions and the possibility of sales of securities up to an overall maximum amount of €20 K per year.

In addition, the Company has made a commitment to abstain for 180 days following the date of settlement-delivery of the Global Offering, subject to the usual exceptions.

Admission to trading of new shares

The new shares will bear dividend rights and will be admitted to trading on the Euronext Growth Paris market under the same ISIN code: FR0013254851 – ALVAL. They will be subject to all statutory provisions and will be ranked with the existing shares upon completion of the fundraise. The settlement-delivery of the new shares and their admission to trading on the Euronext Growth Paris market is scheduled November 11, 2022

The information presented in this press release is so following the placement of shares through an accelerated bookbuilding process and the PrimaryBid platform, now closed, but remains subject to the correct execution of the settlement-delivery operations. The Offer has not resulted in or will not result in the preparation of a prospectus submitted to the AMF for approval.

Risk factors

The public's attention is drawn to the risk factors relating to Valbiotis and its business, presented in Chapter 3 of the Universal Registration Document filed with the AMF (French Financial Markets Authority) on May 19, 2022 under number D.22-0451 and in the amendment to the 2021 Universal Registration Document filed with the AMF on November 8, 2022 which are available free of charge on Valbiotis' website (https://www.valbiotis.com/informations-reglementees/). The occurrence of some or all of these risks could have an adverse effect on Valbiotis' business, financial position, results, development or prospects. The risk factors presented in said documents are identical as of the date of this press release.

In addition, investors are invited to take into consideration the following risks specific to the issue:

the market price of Valbiotis shares could fluctuate and fall below the subscription price of the new shares issued in the context of the transaction;due to fluctuations in the stock markets, the volatility and liquidity of the Valbiotis shares may vary significantly;sales of Valbiotis shares may occur on the secondary market after the completion of the transaction and have an unfavorable impact on the Valbiotis share price;Valbiotis' shareholders could suffer additional dilution as a result of any future capital increases;as the securities are not intended to be listed on a regulated market, investors will not benefit from the guarantees associated with regulated markets.

Such events could have a material adverse effect on the market price of Valbiotis' shares.

This press release does not constitute a prospectus under Regulation (EU) 2017/1129 of the European Parliament and of the Council of 14 June 2017, as amended, or an offer to the public

About Valbiotis

Valbiotis is a Research & Development company committed to scientific innovation for preventing and combating metabolic and cardiovascular diseases in response to unmet medical needs.

Valbiotis has adopted an innovative approach, aiming to revolutionize healthcare by developing a new class of health nutrition products designed to reduce the risk of major metabolic diseases, relying on a multi-target strategy enabled by the use of plant-based terrestrial and marine resources.

Its products are intended to be licensed to players in the health sector.

Created at the beginning of 2014 in La Rochelle, the Company has forged numerous partnerships with leading academic centers. The Company has established three sites in France – Périgny, La Rochelle (17) and Riom (63) – and a subsidiary in Quebec City (Canada).

Valbiotis is a member of the "BPI Excellence" network and has been recognized as an "Innovative Company" by the BPI label. Valbiotis has also been awarded "Young Innovative Company" status and has received major financial support from the European Union for its research programs via the European Regional Development Fund (ERDF). Valbiotis is a PEA-SME eligible company.

For more information about Valbiotis, please visit: www.valbiotis.com

Name: Valbiotis
ISIN code: FR0013254851
Ticker symbol: ALVAL
EnterNext© PEA-PME 150

This press release contains forward-looking statements about Valbiotis’ objectives. Valbiotis considers that these projections are based on rational hypotheses and the information available to Valbiotis at the present time. However, in no way does this constitute a guarantee of future performance, and these projections may be affected by changes in economic conditions and financial markets, as well as certain risks and uncertainties, including those described in the Valbiotis Universal Registration Document filed to the French Financial Markets Regulator (AMF) on May 19, 2022 and completed by an amendment on November 8, 2022. This document is available on the Company’s website (www.valbiotis.com).

This press release and the information it contains do not constitute an offer to sell or subscribe, or a solicitation to purchase or subscribe to Valbiotis’ shares or financial securities in any country.

@ businesswire.com